Synthesis and Characterization of Related Substances Observed in Macitentan, an Endothelien Receptor Antagonist

Authors

  • Kunal M. Jagtap  Department of Process Research and Development, Megafine Pharma (P) Ltd., Lakhmapur, Dindori, Nashik, Maharashtra, India
  • Raghunath B. Toche  Organic Chemistry Research Center, Department of Chemistry, K. T.H.M College, Nashik, Maharashtra, India
  • Vijayavitthal T. Mathad  Department of Process Research and Development, Megafine Pharma (P) Ltd., Lakhmapur, Dindori, Nashik, Maharashtra, India

Keywords:

Macitentan, Antagonist, Impurities, Synthesis.

Abstract

During the process development of Macitentan (1), four related substance (impurities) were detected by high performance liquid chromatography (HPLC) in the final crude material ranging from 0.20 to 0.50% and these are identified by Liquid chromatography-mass spectrometry (LC–MS). All impurities were subsequently synthesized, characterized by spectroscopic techniques and further analyzed and confirmed by chromatographic techniques by spiking and purging study and this impurities are namely 2, 2’-{[5-(4-bromophenyl) pyrimidine-4,6-diyl]bis(oxy)}diethanol (8), 5-(4-bromo-phenyl)-4,6-bis-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]- pyrimidine (9), N-[5-(4-bromophenyl)-6-(2-{[5-(4-bromophenyl)-6-chloropyrimidin-4-yl]oxy}ethoxy)-4-pyrimidinyl] -N’-propylsulfamide (10) and 2-{[5-(4-bromophenyl)-6-{[(propylamino)sulfonyl]amino} pyrimidin-4-yl]oxy}ethylacetate (11).

References

  1. Hong, I.S., Coe, H.V., & Catanzaro, L.M. (2014). Macitentan for the treatment of pulmonary arterial hypertension. The Annals of Pharmacotherapy, 48, 1-10.
  2. Iglarz, M., Qiu, C., Fischli, W., Morrison, K., Binkert, C., Clozel, M., Hess, P., Capeleto, B., Buchmann, S., Boss, C., Bolli, M.H., Weller, T., Treiber, A., & Gatfield, J. (2008). Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. Journal of Pharmacology and Experimental Therapeutics, 327(3), 736-745
  3. Gatfield, J., Grandjean, C. M., Sasse, T., Clozel, M., & Nayler, O. (2012). Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE, 7(10), e47662.
  4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Goto K, Masaki T (1988) Nature 332:411
  5. Battistini B, Botting R, Endothelins (1995) Drug News Persp 8:365
  6. Kohan DE (2008) Curr Hypertens Rep 10:65
  7. Thorin E, Clozel M (2010) Adv Pharmacol 60:1
  8. International Conference on Harmonization guidelines Q3A (R) Impurities in New Drug Substances February 2002 (this guideline provides guidance for registration application on the content and qualification of impurities in new drug substances produced by the chemical synthesis) 18 October 2016.
  9. Bolli MH, Boss C, Binkert C, Clozel M, Fischli W, Weller T (2006) Sulfamide and their use as endothelin receptor antagonist. US Patent 7,094,781B2, Aug 22, 2006; (2006).
  10. Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T (2012) J Med Chem 55:7849

International Journal of Scientific Research in Science and Technology

Downloads

Published

2017-12-31

Issue

Volume 3, Issue 10, November-December-2017

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Kunal M. Jagtap, Raghunath B. Toche, Vijayavitthal T. Mathad, " Synthesis and Characterization of Related Substances Observed in Macitentan, an Endothelien Receptor Antagonist, International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 3, Issue 10, pp.137-141, November-December-2017.